Theresa Klinger

Theresa Klinger

Auto-generated profile, based on publicly available information

Theresa Klinger

Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2024 in Dermatology and Therapy
Verified
Journal Article
Open access
PDF file
KHKristina Hagenström
Kristina Hagenström
KMKatharina Müller
Katharina Müller
TKTheresa Klinger
Theresa Klinger
BSBrigitte Stephan
Brigitte Stephan
MAMatthias Augustin
Matthias Augustin
Introduction Acne is the most frequent chronic inflammatory skin condition in adolescence but occurs also in later age. Our study aimed to characterise the epidemiology, geographical distribution, comorbidity and healthcare of acne juvenilis (AJ) and acne tarda (AT). Methods Statutory health insurance (SHI) data from 2016 to 2020 were analysed. Prevalence rates, including geographical distribution, comorbidities and drug use by specialists group, were measured. Results In 2020, the prevalence of acne among adults was 1.50% (AT > 25 years) and among adolescents was 3.88% (AT ≤ 25 years). The highest prevalence (13.02%) was observed at the age of 17 years. Sex differences were higher in AT (73.80% in women) than in AJ (64.55% in women). Compared with non-affected persons, individuals with acne – in particular with AT – showed significantly higher rates of skin-related comorbidities, including folliculitis (rate ratio (RR) 8.89), pyoderma (RR 7.27) and rosacea (RR 5.53), and non-skin-related comorbidities, such as ovarian dysfunction (RR 2.36), rhinitis allergica (RR 1.84) and Crohn’s disease (RR 1.79). Preferred systemic therapeutics prescribed were anti-infectives in AT (46.86%) and retinoids in AJ (52.35%). In the majority of cases, dermatologists were involved in the treatment of acne (AT 65.77%; AJ 76.27%). The most commonly prescribed topical agents were adapalene with benzoyl peroxide (AT 87.72%; AJ 85.75%), while systemic isotretinoin (AT 81.20%; AJ 90.06%) was also a frequently used drug. General practitioners were more likely to prescribe anti-infectives, especially topical antibiotics such as chlortetracycline (AT 52.38%; AJ 44.44%) and systemic antibiotics, especially tetracycline (AT 58.33%; AJ 67.50%). Conclusion Acne affects a relevant proportion of the German population not only in adolescence, and management of this inflammatory skin disease does not naturally follow medical guidelines or specialist recommendations. These findings emphasise the importance of specialised care and comprehensive therapeutic management that should also consider the exploration of comorbidities.

16 November 2025 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
KHKristina Hagenström
Kristina Hagenström
KMKatharina Müller
Katharina Müller
TKTheresa Klinger
Theresa Klinger
CWCharlotte Willers
Charlotte Willers
KEKilian Eyerich
Kilian Eyerich
MAMatthias Augustin
Matthias Augustin
Summary: Background and Objectives: Nummular eczema (NE) is a chronic skin condition with limited epidemiologic data. This study estimates its prevalence, incidence and severity in Germany. Methods: A cross‐sectional analysis (2016–2022) used German insurance claims data to identify NE cases (ICD‐10 L30.0) and assess severity (hospitalization, work disability, systemic treatment) and comorbid skin conditions, including atopic dermatitis (AD). Results: In 2022, the prevalence of NE ranged from 0.07% to 0.26%. The incidence was 0.16%–0.17%. The mean age was 47.5 years, and 57.4% of the patients were male. Older males had a higher prevalence, while children younger than six years (0.34%), especially those younger than 2 years (0.56%–0.57%), were more affected. Severe NE was found in 14.8% of the patients. AD co‐occurred in 18% of NE cases. NE patients had an increased risk of lichen simplex chronicus (RR 9.71), irritant contact dermatitis (RR 9.60), pruritus (RR 5.71), allergic rhinitis (RR 1.78), and allergic asthma (RR 1.49). Conclusions: Despite differences in methodological approaches leading to some variation, the prevalence of NE in the German population can be reasonably estimated at approximately 0.26%. Overlaps and miscoding may have occurred, particularly with other forms of eczema, underscoring the need for reliable diagnostics and standardized coding.

1 June 2025 in Psoriasis: Targets and Therapy
Verified
Journal Article
Open access
PDF file
KHKristina Hagenström
Kristina Hagenström
TKTheresa Klinger
Theresa Klinger
BSBrigitte Stephan
Brigitte Stephan
MAMatthias Augustin
Matthias Augustin
Purpose: The management of psoriasis has undergone substantial evolution; however, the long-term prescription trends remain ambiguous. This study utilised a comprehensive data set of psoriasis drug prescriptions in Germany from 2010 to 2022, with the objective of evaluating the evolution of treatment modalities over time. Methods: A retrospective longitudinal claims data analysis on systemic biologicals, non-biologicals, and topical treatments for psoriasis was conducted covering prescription rates, medical costs from the payer’s perspective, and defined daily doses (DDDs). Results: Psoriasis prevalence increased slightly from 2.6% in 2010 to 2.7% in 2022. During this period, the proportion of persons receiving prescriptions rose from 55.0% in 2010 to 57.4% in 2022. By 2022, 46.2% of these persons received topical treatments, 13.0% systemic glucocorticosteroids (SCS), 6.7% non-biologicals, and 6.2% biologicals. Compared to 2010, the use of biologicals increased by 449.8%, SCS by 12.6%, non-biologicals by 13.9%, while topical treatments decreased by 3.2%. The annual cost per person treated with a biologic decreased from € 16,315 to € 13,412, while non-biologic and topical therapy costs increased slightly. Adalimumab was the most frequently prescribed systemic drug, followed by ustekinumab and secukinumab. The highest mean costs per-person were for ustekinumab (€ 19,717) and risankizumab (€ 16,986). Conclusion: In more than a decade, the use of innovative systemic drugs, especially biologicals, in Germany has increased substantially. Despite their high cost, biologic expenses per person have slightly decreased over time.

29 April 2026 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
PDF file
TKTheresa Klinger
Theresa Klinger
MAMatthias Augustin
Matthias Augustin
SBSusanne Baumeister
Susanne Baumeister
JRJennifer Riedel
Jennifer Riedel
CGClaudia Grellmann
Claudia Grellmann
KHKristina Hagenström
Kristina Hagenström
Vitiligo is a chronic skin disease resulting in destruction of melanocytes and loss of pigmentation. Little is known about epidemiology and comorbidity in Germany. This retrospective cohort analysis used nationwide statutory health insurance data (2016 to 2020). Disease rates were calculated using varying case definitions. Comorbidity was assessed against 3 control groups: persons without vitiligo, with atopic dermatitis, and with psoriasis (1:3 propensity score matching). In 2020, 4,631 persons were diagnosed with vitiligo in DAK-Gesundheit (DAK-G, mean age 56.93 years, ~148,437) and 5,820 persons in the German Analysis Database for Evaluation and Health Services Research (~144,855). Prevalence ranged from 0.12% (confidence interval [CI] 0.12–0.12) to 0.20% (CI 0.19–0.20), and incidence from 0.04% (CI 0.03–0.04) to 0.06% (CI 0.06–0.06). Rates increased with age. Women (mean age 58.60 years) were more frequently affected. Vitiligo was associated with alopecia areata (relative risk 7.14, CI 4.63–11.00) and systemic sclerosis (relative risk 3.20, CI 1.58–6.47). Several mental illnesses (depression: relative risk = 1.23, CI 1.15–1.32, anxiety: relative risk = 1.32, CI 1.19–1.47), were linked to skin diseases like vitiligo, atopic dermatitis, or psoriasis. Vitiligo affects a notable proportion of the population, with detected comorbidities supporting prior findings. To ensure reliable results, claims data should be validated through primary data linkage or sensitivity testing.

4 March 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
TKTheresa Klinger
Theresa Klinger
MAMatthias Augustin
Matthias Augustin
GLGregor Leicht
Gregor Leicht
SMSteffen Moritz
Steffen Moritz
KHKristina Hagenström
Kristina Hagenström
Objectives To estimate the prevalence and comorbidity patterns of mental health disorders (MHDs) in persons with vitiligo and compare relative risks (RRs) with dermatological diseases (atopic dermatitis and psoriasis) and non-vitiligo comparator cohorts using claims data. Design Retrospective matched cohort study using nationwide statutory health insurance claims data. Setting German statutory health insurance claims (DAK-Gesundheit), 2016–2020. Participants A 40% anonymised sample of insured persons (N=2 885 984). In 2020, persons with vitiligo (International Statistical Classification of Diseases, Tenth Revision, German Modification L80) were compared with cohorts with atopic dermatitis (L20), psoriasis (L40) and persons without vitiligo. Cohorts were propensity score matched (1:3) by age and sex. Primary outcome measures Prevalence of MHDs and RRs across comparator cohorts. Secondary outcome measures Internal plausibility of expert-informed claims-based MHD case definitions using diagnosis-only versus diagnosis-plus-care criteria. Results In 2020, 4 631 persons were diagnosed with vitiligo. Affective disorders and neurotic, stress-related and somatoform disorders showed the highest prevalence, with depressive episodes ranging from 8.9% to 19.2% and somatoform disorders from 5.3% to 17.9% across definitions. In matched comparisons with atopic dermatitis, only a few and inconsistent differences were observed. In contrast, more pronounced and consistent differences were identified in comparisons with psoriasis. Emotional disorders in childhood showed higher risks under the most sensitive case definition (RR=2.29, 95% CI 1.14 to 4.61), whereas hyperkinetic disorders showed consistent effects across all definitions (RR range=1.58–1.93). Compared with persons without vitiligo, risks were higher for social phobia (RR range=2.10–2.81) and anxiety disorders (RR range=1.64–1.93). Conclusions Persons with vitiligo show a substantial burden of affective and stress-related MHDs. The mental health comorbidity profile was largely comparable to that of atopic dermatitis, whereas more pronounced differences were observed in comparisons with psoriasis. Claims-based prevalence estimates were sensitive to case definition, highlighting the importance of transparent operationalisation.

22 June 2026 in Dermatology and Therapy
Verified
Journal Article
Open access
TKTheresa Klinger
Theresa Klinger
KMKatharina Müller
Katharina Müller
RGRicarda Graf
Ricarda Graf
MAMatthias Augustin
Matthias Augustin
KHKristina Hagenström
Kristina Hagenström
Systemic glucocorticosteroids (SGCs) are recommended only for short-term treatment of atopic dermatitis (AD) because of their side effect profile. Nevertheless, prolonged and repeated use remains common in routine care. Evidence on whether treatment duration or cumulative dose is the main driver of adverse events is limited. Therefore, the aim of this study is to investigate the longitudinal association between SGC treatment duration and side effects in persons with AD and to compare its impact with cumulative dose. This was a retrospective cohort study based on German statutory health insurance data that included persons with AD initiating SGC therapy. Associations between SGC exposure and side effect were analyzed using logistic regression and adjusted time-dependent Cox models. Longer treatment duration was associated with higher odds of multiple side effects, including osteoporosis (odds ratio [OR] 1.21-1.27). In time-dependent Cox models, each additional quarter of SGC therapy increased the hazard of mental disorders (hazard ratio [HR] 1.21; 95% confidence interval [CI] 1.10-1.32), gastritis/duodenitis (HR 1.07; 1.00-1.15), osteoporosis (HR 1.37; 1.23-1.52), hypertension (HR 1.26; 1.08-1.48), and diabetes mellitus (HR 1.35; 1.09-1.69). Prolonged SGC therapy is associated with increasing risks of multiple side effects, supporting guideline recommendations for short-term use only. Documented SGC treatment duration showed more consistent associations with side effects than cumulative dose.